46th week of 2014 patent applcation highlights part 49 |
Patent application number | Title | Published |
20140336182 | Aurora Kinase Modulators and Method of Use - The present invention relates to chemical compounds having a general formula I | 2014-11-13 |
20140336183 | Compositions And Method For Treatment Of Ischemic Neuronal Reperfusion Injury - A method and composition for the treatment of ischemic neuronal reperfusion injury are provided. The composition may include at least a benzodiazepine class material. In another form, the composition may include at least two components selected from the group consisting of an antagonist of the type 3 ryanodine receptor, an NMDA blocker (antagonist), and a benzodiazepine class material which can be administered for ischemic neuronal reperfusion injury. In one form, all three components may be used. | 2014-11-13 |
20140336184 | METHOD TO ENHANCE COGNITION - The present invention concerns methods and compositions regarding suppression of double stranded RNA-activated protein kinase (PKR) to enhance cognition in an individual. In specific cases, an inhibitor of PKR is provided to the individual such that cognition is enhanced thereby, including by enhancing memory, for example. Kits are encompassed in certain embodiments. | 2014-11-13 |
20140336185 | NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS - Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP (1-42), PTH (1-34), Glucagon (1-29), GLP-2 (1-33), GLP-1 (7-36), GLP-1 (9-36), oxyntomodulin and exendin variants. | 2014-11-13 |
20140336186 | Heterocyclic Compounds as Pesticides - The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests, including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation. | 2014-11-13 |
20140336187 | METHODS FOR TREATING LEISHMANIASIS - Methods are provided to inhibit proliferation of | 2014-11-13 |
20140336188 | N-SUBSTITUTED INDENOISOQUINOLINES AND SYNTHESES THEREOF - N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof. | 2014-11-13 |
20140336189 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - Compounds corresponding to the general formula (I) | 2014-11-13 |
20140336190 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS - This application relates to chemical compounds which may act as inhibitors of; or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) | 2014-11-13 |
20140336191 | QUINOLINYLOXYPHENYLSULFONAMIDES - The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases. | 2014-11-13 |
20140336192 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS - There are provided substituted 3-phenyl-isoquinolin-1(2H)-one derivatives which selectively inhibit the activity of poly(ADP-ribose) polymerase PARP-1 with respect to poly(ADP-ribose) polymerase PARP-2. The compounds of the present invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds. | 2014-11-13 |
20140336193 | POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE - The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension. | 2014-11-13 |
20140336194 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY - The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: | 2014-11-13 |
20140336195 | ARYLOXMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS - The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. | 2014-11-13 |
20140336196 | PHOSPHORIC ACID SALTS OF SITAGLIPTIN - The present invention relates to novel phosphoric acid salts of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine, and polymorphs, hydrates and solvates thereof, which are potent inhibitors of dipeptidyl peptidase-IV useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The present invention also relates to the process for preparing the novel phosphoric acid salts of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine, as well as pharmaceutical compositions containing the novel phosphoric acid salts, and methods of use thereof for the treatment of diabetes, obesity, and high blood pressure. | 2014-11-13 |
20140336197 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR - The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) | 2014-11-13 |
20140336198 | Amine Derivatives as Potassium Channel Blockers - The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation. | 2014-11-13 |
20140336199 | Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors - This invention is related to the alkyl-piperazine-phenyl 4(3H)-quinazolinones compounds of general formula (I) below: | 2014-11-13 |
20140336200 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES - Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system. | 2014-11-13 |
20140336201 | BIPYRIDYL DERIVATIVES - The present invention relates to novel bipyridyl derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors. | 2014-11-13 |
20140336202 | METHODS OF IDENTIFYING AND USING MDM2 INHIBITORS - Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of treating subjects with cancers that have, or develop in response to treatment with tyrosine kinase inhibitors, elevated levels of MDM2, Mcl-1 or PP5 or decreased levels of Huwe1 or CAS using MDM2 inhibitors are provided herein. The MDM2 inhibitors may be effective at treating these cancers alone or in combination with a tyrosine kinase inhibitor regardless of p53 status (mutant or wild-type) of the cancer. | 2014-11-13 |
20140336203 | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR - Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2014-11-13 |
20140336204 | METHODS OF INHIBITING XANTHINE OXIDASE ACTIVITY IN A CELL - Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia. | 2014-11-13 |
20140336205 | Small Molecule Xanthine Oxidase Inhibitors and Methods of Use - Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia. | 2014-11-13 |
20140336206 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2014-11-13 |
20140336207 | PYRROLE SIX-MEMBERED HETEROARYL RING DERIVATIVE, PREPARATION METHOD THEREOF, AND MEDICINAL USES THEREOF - The present invention relates to a pyrrole six-membered heteroaryl ring derivative, the preparation method therefor, and the medicinal uses thereof. Specifically, the present invention relates to a new pyrrole six-membered herteroaryl ring derivative as represented by formula (I), the preparation method therefor, a medicinal composition comprising the derivative, and a therapeutic method using same, and, in particular, the uses as a JAK inhibitor and an immunosuppressor. Substituents in formula (I) have the same definitions as in the description. | 2014-11-13 |
20140336208 | 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS - This invention relates to compounds of the formula | 2014-11-13 |
20140336209 | NITROGEN-CONTAINING SIX-MEMBERED AROMATIC RING DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME - Provided is a compound that has the ability to promote axonal outgrowth in combination with the ability to promote angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases such as myocardial infarction and organic angina, peripheral arterial occlusive diseases such as critical limb ischemia, or after-effects of these diseases. Specifically, the compound is represented by the following formula (I): | 2014-11-13 |
20140336210 | ARYL UREA COMPOUNDS IN COMBINATION WITH OTHER CYTOSTATIC OR CYTOTOXIC AGENTS FOR TREATING HUMAN CANCERS - This invention relates to aryl urea compounds in combination with cytotoxic or cytostatic agents for use in treating raf kinase mediated diseases such as cancer. | 2014-11-13 |
20140336211 | Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1H-Indole-5-carboxylic acid [ (S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino) -ethyl ] -amide - The present invention relates to polymorphs and hydrates of 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [(S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide, processes for their preparation and their use, in particular in pharmaceutical compositions. | 2014-11-13 |
20140336213 | Abuse Deterrent Compositions and Methods of Making Same - This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a disintegrant; and a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile. | 2014-11-13 |
20140336215 | Rhinitis Treatment Regimens - A method of treating rhinitis and rhinorrhea includes taking a daytime oral dosage unit containing a non-sedating antihistamine for treating rhinitis and an anticholinergic agent having limited capacity to cross blood-brain barrier for treating rhinorrhea, and taking a nighttime oral dosage unit containing a non-sedating anticholinergic agent that has limited capacity to cross blood-brain barrier and that is in a lower amount than the amount in the daytime oral dosage unit for treating rhinorrhea or no anticholinergic agent. A treatment regimen for rhinitis with rhinorrhea includes a daytime oral dosage unit containing a non-sedating antihistamine for treating rhinitis and an anticholinergic agent having limited capacity to cross blood-brain barrier for treating rhinorrhea, and a nighttime dosage unit containing a non-sedating anticholinergic agent that has limited capacity to cross blood-brain barrier and that is in a lower amount than the amount in the daytime oral dosage unit for treating rhinorrhea or no anticholinergic agent. | 2014-11-13 |
20140336216 | PHYSIOLOGICAL LIGANDS FOR GPR139 - Provided herein are compounds capable of activating GPR139. Also provided are methods of increasing and decreasing the activity of GPR139. Methods of using the identified compounds to modulate GPR139 activity or conditions that may be affected by GPR139 activity are also disclosed. | 2014-11-13 |
20140336217 | Crystalline Forms Of Prasugrel Salts - Salts of prasugrel were prepared including, for example, crystalline forms of prasugrel hydro bromide. These salts are useful, for example, in medicaments that inhibit the aggregation of platelets. | 2014-11-13 |
20140336219 | Pharmaceutical Compositions and Administrations Thereof - The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. | 2014-11-13 |
20140336220 | COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING REBAMIPIDE - The present disclosure relates to a composition and a health functional food for preventing or treating obesity comprising a rebamipide compound or its pharmaceutically acceptable salt as an active component. It is confirmed that when a rebamipide compound of the present disclosure is administered to a mouse model induced with obesity, it shows excellent effects of reducing weight, reducing adipocyte, and reducing a total cholesterol content in the body, as compared with a non-administered control group, and also, it shows an excellent effect of suppressing differentiation of cytotoxic Th17 cells that generate and secrets inflammatory cytokine and an excellent effect of improving activity of regulatory T cells (Treg) capable of suppressing a function of abnormally activated immune cells and controlling an inflammatory reaction. Thus, the rebamipide compound can be used for producing a medicine and a functional food which can effectively treat obesity caused by abnormality of immune modulation. | 2014-11-13 |
20140336221 | Antibiotic and Anti-Parasitic Agents that Modulate Class II Fructose 1, 6-Bisphosphate Aldolase - This invention provides a family of compounds that inhibit Class II fructose 1,6-bisphosphate aldolase (FBA), which is implicated in the pathogenic activity of a broad range of bacterial and parasitic agents. The compounds were identified by empirical testing, and provide a basis for further derivatization and optimization of 8-hydroxyquinoline-2-carboxylic acid and related compounds. Crystal structure shows that the compounds don't bind directly to the catalytic site of the enzyme, and so are not defined simply as substrate analogs. Instead, they create a pocket by induced fit, resulting a powerful and specific inhibitory effect on FBA activity. | 2014-11-13 |
20140336222 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF - The present invention provides a compound of Formula 1 | 2014-11-13 |
20140336223 | FORMULATIONS OF 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE - Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease. | 2014-11-13 |
20140336224 | MINERALOCORTICOID RECEPTOR ANTAGONISTS - Compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases are disclosed. Processes for preparing compounds of the Formula (I), use of the compounds for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and pharmaceutical compositions which comprise compounds of the Formula (I) are disclosed. | 2014-11-13 |
20140336225 | KINASE MODULATORS FOR THE TREATMENT OF CANCER - Compounds of the substituted pyrazole class as treatments for cancer are reported. A method of treating cancer in which a compound that inhibits the activity of receptor kinases. Said method is effective and can be provided in addition to standard therapies, notably chemotherapy using cytotoxic drugs and other forms of immune therapy including therapeutic vaccines. | 2014-11-13 |
20140336226 | Salt Of (R)-3-(6-Amino-Pyridin-3-Yl)-2-(1-Cyclohexyl-1H-Imidazol-4-Yl) Ethyl Propionate - The invention relates to the salt of naphthalene-1,5-disulfonic acid with (R)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)ethyl propionate, which can be represented by the following structural formula of formula (I), to methods for the production thereof, to drugs containing said salt, and to the use of said drugs to treat diseases that are accompanied by thromboses, embolisms, hypercoagulability, or fibrotic changes. | 2014-11-13 |
20140336227 | 3-AMINO LACTAMS AS ANTI-INFLAMMATORY AGENTS - Compounds, pharmaceutical compositions of general formula (I) or (I′) or a pharmaceutically acceptable salt thereof, and methods for treating an inflammatory disorder: | 2014-11-13 |
20140336228 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HYPERTRIGLYCERIDEMIA OR HYPERTRIGLYCERIDEMIA-ASSOCIATED DISEASES - Provided is a pharmaceutical composition for preventing or treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt; and a calcium channel blocker or a fibrate as active ingredients. | 2014-11-13 |
20140336229 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA - Provided is a pharmaceutical composition for preventing or treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt; and an angiotensin II receptor blocker as active ingredients. | 2014-11-13 |
20140336230 | METHOD OF INCREASING METABOLISM - The present invention provides a method for increasing metabolism and/or energy expenditure in a subject, e.g., to treat or prevent obesity and/or a related condition and/or the reduce adiposity, the method comprising increasing the level and/or activity of Hypoxia Induced Factor 1α (HIF-1α) in a cell, tissue or organ of the subject, thereby increasing metabolism in the subject. The present invention also provides a method for increasing metabolism in a subject, the method comprising administering an iron chelating agent to the subject, thereby increasing metabolism in the subject. | 2014-11-13 |
20140336231 | ACTIVE COMPOUNDS COMBINATIONS COMPRISING PROTHIOCONAZOLE AND FLUXAPYROXAD - The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) prothioconazole and (B) fluxapyroxad and optionally (C) a further fungicidally active compound. Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungicidally of plants or crops (e.g. cereals such as wheat, barley, lye, oats, millet and triticale; soya beans; rice; corn/maize; oil seed rape including canola; beans, peas, peanuts; sugar beet, fodder beet, beetroot; potatoes; cotton), and to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed. | 2014-11-13 |
20140336232 | 2-IODO IMIDAZOLE-DERIVATIVES - The present invention relates to novel 2-iodoimidazole derivatives, to processes for preparing these compounds, to compositions comprising these compounds and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators. | 2014-11-13 |
20140336233 | USE OF TETRAMIC ACID DERIVATIVES FOR CONTROLLING PATHOGENS BY FOLIAR APPLICATION - Compounds of the formulae (I) and (II) for controlling pathogens by foliar application. | 2014-11-13 |
20140336234 | CHLOROPHYLL c CONTAINING DEGRANULATION SUPPRESSOR - Degranulation suppressors are provided that are effective against allergic disease and osteoarthritis. The degranulation suppressors contain chlorophyll c. | 2014-11-13 |
20140336235 | SUBSTITUTED BIARYL ALKYL AMIDES - Disclosed herein are substituted biaryl alkyl amide compounds, methods of synthesizing substituted biaryl alkyl amide compounds and methods of treating diseases and/or conditions with substituted biaryl alkyl amide compounds. | 2014-11-13 |
20140336236 | NOVEL ALK AND NTRK1 FUSION MOLECULES AND USES THEREOF - Novel ALK and NTRK1 fusion molecules and uses are disclosed. | 2014-11-13 |
20140336237 | MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION - Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases. | 2014-11-13 |
20140336238 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS - The present invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis. | 2014-11-13 |
20140336239 | COMPOSITIONS AND METHODS FOR MODULATING MYELOID DERIVED SUPPRESSOR CELLS - Provided are methods and compositions for modulating the differentiation of a myeloid derived suppressor cell (MDSC). In particular, described herein are miR-142 polynucleotides and miR-223 polynucleotides that can be used to modulate differentiation of MDSCs. Increased differentiation of a MDSC population, or cells within an MDSC population, can be achieved by increasing the miR-142 and/or miR-223 polynucleotides in a MDSC. | 2014-11-13 |
20140336240 | METHOD OF TREATING HYPERLIPIDEMIA AND ATHEROSCLEROSIS WITH MIR-30C - This disclosure provides a novel role for microRNA (miR) regulation of lipid metabolism via the MTP pathway, leading to reductions in apoB secretion and blood lipid levels. MiR regulation of the MTP pathway is shown herein to reduce hyperlipidemia and atherosclerosis in vivo. Therefore, inhibition of MTP expression and activity by miR regulation is identified as a new therapeutic target for treatment of cardiovascular disease and conditions or diseases associated with cardiovascular disease such as hyperlipidemia, atherosclerosis, and metabolic syndrome. Treatment of cardiovascular disease and associated conditions or diseases with the novel MTP inhibitors of the invention, such as miR-30c homologs or miR-30c agonists, reduces MTP-associated lipid production without side effects that occur with other methods of MTP inhibition. | 2014-11-13 |
20140336241 | COMPOSITIONS AND METHODS FOR PROGNOSIS AND TREATMENT OF PROSTATE CANCER - Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of prostate cancer, as well as various nucleic acid molecules relating thereto or derived therefrom. | 2014-11-13 |
20140336242 | Micro-RNA Scaffolds and Non-naturally Occurring Micro-RNAs - The present disclosure provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from a first endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand derived from a second endogenous miRNA, and a star strand sequence that is at least partially complementary to the mature strand sequence. The present disclosure also provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from an endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand designed to be at least partially complementary to a target RNA, and a star strand sequence that is at least partially complementary to the mature strand sequence. The methods and compositions of the disclosure may be used to mediate gene silencing via the RNAi pathway. | 2014-11-13 |
20140336243 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as cancer. | 2014-11-13 |
20140336244 | METHODS AND PRODUCTS FOR REAWAKENING RETROCYCLINS - Products and methods are provided for the restoring the endogenous expression of theta-defensins, such as retrocyclin-1, in mamallian cells. The present invention also includes products and methods for inhibiting sexually transmitted virus entry, e.g., HIV-1 virus entry, into a mammalian cell via, for example, administering to a subject an amount of a read-through mediating agent sufficient to induce exogenous expression of an amount of retrocyclin nonapeptides in the mammalian cell. | 2014-11-13 |
20140336245 | VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENE DELIVERY - The invention provides viral vector formulations and methods of uses thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. The formulations include a vector and suitable amounts of empty capsids, viral genome-containing capsids, or viral capsid proteins which are optionally chemically or structurally modified and which bind to neutralizing anti-AAV antibodies thereby reducing or preventing antibody-mediated clearance of the vector, but still allowing the genome-containing (therapeutic) vector to transduce target cells and achieve therapeutic gene transfer. | 2014-11-13 |
20140336246 | PROCESS FOR PREPARING AMORPHOUS CABAZITAXEL - The present invention provides a non-solvated amorphous form of (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I), | 2014-11-13 |
20140336247 | DAIDZEIN DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - Disclosed is a daidzein derivative as represented by formula (I), or pharmaceutically acceptable salt thereof. Compared to the daidzein in the prior art, the daidzein derivative hydrochloride, in particular to the 7-O—N,N-diethyl-aminoacetyl daidzein hydrochloride, prepared by the daidzein derivative of the present invention, has better solubility and effect for treating cardiovascular diseases. | 2014-11-13 |
20140336248 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE - Aqueous compositions comprising salinomycin, or a pharmaceutically acceptable salt thereof, miscible organic solvents, and solubilizers and/or emulsifying agents are disclosed. The formulations disclosed herein are useful in the treatment of cancer, especially cancers associated with cancer stem cells or cancerous mesenchymal cells. The method of treating a subject may further comprise identifying a subject having a disorder suitable for treatment with the aqueous compositions described, comprising detecting one or more biomarkers predictive of the prevalence of a cancer having or enriched for cancer stem cells (CSCs). | 2014-11-13 |
20140336249 | 2-ALKYL-OR-ARYL-SUBSTITUTED TANSHINONE DERIVATIVES, AND PREPARATION METHOD AND APPLICATION THEREOF - The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and specifically relates to novel 2-alkyl- or 2-aromatic-substituted tanshinone I derivatives of formula (I) or a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments. When Z═R, said derivative is 2-alkyl-substituted tanshinone I; when Z═Ar, said derivative is 2-aryl-substituted tanshinone I; when Z=Het, said derivative is 2-heteroaryl- or 2-heterocyclyl-substituted tanshinone I. | 2014-11-13 |
20140336250 | METHOD FOR TREATING BRONCHIAL DISEASES - Administration of a loop diuretic in nebulized dry powder form directly to a patient's lungs for treating bronchial disease. | 2014-11-13 |
20140336251 | METHODS OF TREATING AGE RELATED DISORDERS - The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically effective amount of a MetAP2 inhibitor. | 2014-11-13 |
20140336252 | NOVEL COMPOUND AS KCNQ POTASSIUM CHANNEL AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF - The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereofagonist, preparation methods therefor and a use thereof in the preparation of a medicine for the treatment of nervous system diseases. The compounds or pharmaceutical compositions thereof can be used as the KCNQ potassium channel agonist for treating nervous system diseases. Compared to retigabine, a compound in the prior art, the compound of the present invention have the same or better therapeutic effect, are easier for synthesis and storage, and less prone to oxidate deterioration. | 2014-11-13 |
20140336253 | COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF RIVASTIGMINE - It has been found that phenyl carbamates, in particular Rivastigmine, can be formulated as a stable TTS by using a monolayer poly alkyl (meth)acrylates, wherein the poly alkyl (meth)acrylates are substantially free of free carboxylate groups. | 2014-11-13 |
20140336254 | Small Molecules That Covalently Modify Transthyretin - A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and | 2014-11-13 |
20140336255 | INSECTICIDAL FORMULATIONS WITH IMPROVED LONG-TERM EFFECT ON SURFACES - The present invention relates to compositions for the control of pests, in particular insecticidal suspension concentrates and spray solutions made from them, to processes for their preparation, and to the use of such formulations for the sustained control of animal pests (arthropods) on a variety of surfaces. The present invention furthermore relates to the use of certain polymer dispersions in pesticides, in particular to their use for extending the long-term activity of these compositions when they are applied to surfaces. The present invention furthermore relates to the use of the compositions according to the invention for controlling parasites, in particular ectoparasites, in animals. | 2014-11-13 |
20140336256 | METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS - The present invention is a method of treating Tourette's Disorder (TD) using GABA ergic drugs that elevate the amount of stored presynaptic GABA and do not significantly increase GABA tone (a continuous background level of GABA signaling) in the brain. The administration of vigabatrin and/or (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride salt is expressly contemplated. | 2014-11-13 |
20140336257 | ADMINISTRATION OF ADAPALENE AND BENZOYL PEROXIDE FOR THE LONG-TERM TREATMENT OF ACNE VULGARIS - A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor. | 2014-11-13 |
20140336258 | ANTI-VIRULENCE COMPOSITIONS AND METHODS - A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium. | 2014-11-13 |
20140336259 | PHENOLIC COMPOUNDS WITH ANTIOXIDANT AND ANTI-CANCER PROPERTIES, ANALOGS AND SYNTHESIS THEREOF - The present document describes a phytochemical isolated from maple syrup and composition comprising the same. More specifically, the document describes an antioxidant phytochemical compound, derivates thereof, and composition comprising the same. The document also describes a process of synthesizing the antioxidant phytochemical compound. | 2014-11-13 |
20140336260 | PRODUCT FOR MOLD PREVENTION AND TREATMENT - A novel product for mold prevention and treatment is disclosed herein. The product comprises water, one or more anti-mold agents, one or more water-soluble fluoropolymers or other water-soluble polymers with similar properties, and one or more emulsifiers. In some embodiments, the product may further comprise one or more preservatives, one or more stabilizers, one or more binders, one or more fining agents, one or more firming agents, one or more thickeners, and/or one or more clarifying agents. The product may be non-toxic, biodegradable, effective for a long-period of time and against a wide variety of molds, and may also provide other features which render it safe for the environment as compared to other commonly used products in mold prevention and treatment. | 2014-11-13 |
20140336261 | METHODS FOR DETERMINING AGGRESSIVENESS OF A CANCER AND TREATMENT THEREOF - The invention generally relates to methods for determining aggressiveness of a cancer and treatment thereof. Certain aspects of the invention provide methods that involve conducting an assay on a lipid droplet in order to detect an amount of a biomarker within the lipid droplet, and determining aggressiveness of a cancer based upon the amount of the biomarker within the lipid droplet. Other aspects of the invention provide methods for treating a cancer that involve administering an agent that blocks storage of cholesteryl ester in a lipid droplet. | 2014-11-13 |
20140336262 | PHARMACEUTICAL COMPOSITIONS COMPRISING NAPTHAMIDES - Disclosed herein are naphthamide and quinoline carboxamide compounds containing two bicyclic moieties, pharmaceutical compositions comprising those compounds and methods of using the compositions in the treatment of cancers mediated by cyclic-AMP (cAMP) response element binding protein (CREB). The disclosed compositions have utility in the treatment of lung, prostate and breast cancers in a human subject. | 2014-11-13 |
20140336263 | ANIMAL DETERRENT SYSTEM AND METHODS THEREOF - An animal deterrent device that generally includes a casing, a sensor, a power source and a deterrent means source. The animal deterrent device is used to provide protection to a target site, such as a carcass or part of a carcass left at or near the kill site from predatory animals and/or scavengers. Other uses for the device include preventing animals from disrupting trash or garbage receptacles or for preventing animals from gaining access to campsite rations, food, a temporary carcass or parts of a carcass storage area, or trash. | 2014-11-13 |
20140336264 | EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE - The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol. | 2014-11-13 |
20140336265 | Dosage Regimen of Diaryl Sulfide Derivatives - A compound of formula I: | 2014-11-13 |
20140336266 | METHOD FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT - Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided. | 2014-11-13 |
20140336267 | UTILIZATION OF THE FUNCTION OF RARE SUGAR AS PROMOTER FOR THE MIGRATION OF GLUCOKINASE FROM NUCLEUS TO CYTOPLASM - A composition for treating disordered conditions in association with glucokinase activity contains a glucokinase-activating substance as the active ingredient. A promoting agent of glucokinase transfer from nucleus to cytoplasm contains D-psicose and/or D-tagatose as the active ingredient or a composition for preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions is in a form selected from a group consisting of food additives, food materials, drinks and foods, health drinks and foods, pharmaceutical product and feeds in blend with D-psicose and/or D-tagatose as the active ingredient for use in preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions, which are selected from impaired glucose tolerance, type 2 diabetes mellitus, insulin resistance, abnormal lipidemia, the metabolic syndrome and obesity. | 2014-11-13 |
20140336268 | FORMULATIONS OF VITAMIN K ANALOGS FOR TOPICAL USE - The present invention provides topical formulations containing a vitamin K analog, e.g., menadione, that deliver a uniform, therapeutically effective concentration of the vitamin K analog to the skin in a vehicle which is stable, non-irritating, non-drying and cosmetically acceptable. These topical formulations are useful for the treatment and prevention of dermatological conditions associated with inflammation, particularly, dermatological conditions resulting from anti-EGFR therapies. | 2014-11-13 |
20140336269 | METHODS AND COMPOSITIONS FOR CONTROLLING PESTS - The present invention is directed to pest-controlling compositions comprising as active ingredients one or more β-diones, particularly β-diketones and β-triketones, and to the use of these compositions inter alia for preventing, eradicating, destroying, repelling or mitigating harmful, annoying or undesired pests including insects, arachnids, helminths, molluscs, protozoa and viruses. The present invention is further directed to processes of preparing β-diones by de novo synthesis or from natural sources such as volatile oil-bearing plants from families including Alliaceae, Apiaceae, Asteraceae, Cannabinaceae, Lamiaceae, Pteridaceae, Myrtaceae, Myoporaceae, Proteaceae, Rutaceae and Zingiberaceae. | 2014-11-13 |
20140336270 | Method for synthesizing (E)-Anethol and Related Compounds By Cross Coupling Reaction of Potassium allyltrifluroborate and 4-bromoanisole and aryl halides - Methods of producing substituted and non-substituted beta-methyl styrene by a cross-coupling reaction are provided. The disclosure also provides for methods of preparing (E)-Anethol and related compounds by a cross coupling reaction of potassium allyltrifluoroborate and 4-bromoanisole and aryl halides. Compounds, compositions, and methods of treating disorders utilizing beta-methyl styrene are also provided. | 2014-11-13 |
20140336271 | Antimicrobial Compositions Containing Carvacrol and Thymol - Compositions having a combination of carvacrol and thymol are found to have synergistic antimicrobial activity against feed pathogens. | 2014-11-13 |
20140336272 | Petrolatum Composition - A petrolatum composition comprises from 10 to 60 wt % of a wax having an average number of carbon atoms per molecule of between 25 and 70, and having between 5 and 50 wt % branched paraffins in which the branches are selected from methyl and ethyl branches; from 10 to 60 wt % of a linear paraffin having an average number of carbon atoms per molecule of between 10 and 20; and optionally, a low melt wax. The petrolatum composition has a drop melt point of from 35° C. to 80° C. | 2014-11-13 |
20140336273 | ANHYDROUS SODIUM CARBONATE HAVING A LOW PORE CONTENT - The present invention relates to a highly pure, anhydrous sodium carbonate having a low pore content for use in pharmaceutical formulations and in the foods industry. Furthermore, a novel process for the preparation of this sodium carbonate is provided. | 2014-11-13 |
20140336274 | PROCESS FOR PRODUCING INORGANIC PARTICULATE MATERIAL - The present invention is directed to a process for producing inorganic particulate material, the material obtainable by such process, a modified release delivery system comprising the material and the use of the material for the administration of a bioactive agent. | 2014-11-13 |
20140336275 | Modular Emulsion-Based Product Differentiation - A micro-scale heterogeneous emulsion is provided. In some examples, the micro-scale heterogeneous emulsion can include at least two internal phases and an external phase. A method of producing a micro-scale heterogeneous emulsion is also disclosed herein. A method of providing a stable, custom cosmetic composition is also disclosed herein. | 2014-11-13 |
20140336276 | IN SITU CROSSLINKING HYDROGEL COMPRISING gamma-POLYGLUTAMIC ACID AND METHOD FOR PRODUCING THE SAME - Disclosed are a biodegradable, biocompatible hydrogel that can be used for sealants of suppressing the leakage of blood or air during surgical operation, tissue adhesives, anti-adhesive agents and drug delivery carriers, and a method for producing the same | 2014-11-13 |
20140336277 | Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof - Radiopaque, iodinated, absorbable polyesters, polyester urethanes, and polyether-ester-urethanes with and without inorganic iodide micro-/nanoparticles dispersed or solubilized therein, and composite inorganic iodide micro-/nanoparticles in an absorbable polyester, polyester-urethane, polyester-ester, or polyether-ester urethane matrix are employed in medical devices and therapeutic compositions. | 2014-11-13 |
20140336278 | In Situ Gelling Drug Delivery System - The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered. | 2014-11-13 |
20140336279 | USE OF A VAPORIZABLE COMPOSITION TO PROTECT CULTIVATED PLANTS FROM PESTS - The disclosure relates to the use of an oil emulsion for acaricidal, insecticidal, and antifungal treatment of the stems and leaves of a plant during the growth thereof in confined, intensive-cultivation spaces, the emulsion including water and a paraffin oil obtained from petroleum and having a boiling point of 200° C. to 450° C., a viscosity of no more than 20 mm | 2014-11-13 |
20140336280 | COMPOSITIONS AND METHODS FOR DETECTING AND DETERMINING A PROGNOSIS FOR PROSTATE CANCER - The present disclosure provides methods of detecting and determining the aggressiveness of prostate cancer. These methods can be used to determine whether or not a patient needs a biopsy as well as guide treatment selection. | 2014-11-13 |
20140336281 | SRM/MRM Assay for the Ephrin Typa-A Receptor 2 Protein - Specific peptides, and derived ionization characteristics of the peptides, from the Ephrin Type-A Receptor 2 (EPHA2) protein are provided that are particularly advantageous for quantifying the EPHA2 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from said biological sample using the Liquid Tissue™ reagents and protocol and the EPHA2 protein is quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of an EPHA2 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. | 2014-11-13 |
20140336282 | MOLECULAR SIGNATURES OF INVASIVE CANCER SUBPOPULATIONS - Carcinomas typically invade as a cohesive multicellular unit, a process termed collective invasion. It remains unclear how different subpopulations of cancer cells contribute to this process. We developed three-dimensional (3D) organoid assays to identify the most invasive cancer cells in primary breast tumors. Collective invasion was led by specialized cancer cells that were defined by their expression of basal epithelial genes, such as cytokeratin-14 (K14) and p63. Furthermore, K14+ cells led collective invasion in the major human breast cancer subtypes. Importantly, lumenal cancer cells were observed to convert phenotypically to invasive leaders following induction of basal epithelial genes. Although only a minority of cells within lumenal tumors expressed basal epithelial genes, knockdown of either K14 or p63 was sufficient to block collective invasion. Our data reveal that heterotypic interactions between epithelial subpopulations are critical to collective invasion. We suggest that targeting the basal invasive program could limit metastatic progression. | 2014-11-13 |
20140336283 | GENETIC FACTORS IN BLOOD PRESSURE - The invention describes epistatic interactions between single nucleotide polymorphisms on genes associated with blood pressure and provides an application for their use in a method to determine an individual's susceptibility to hypertension and hence whether anti-hypertensive treatment will be beneficial for said individual. In addition gene expression levels are also linked to blood pressure and may also be used to determine susceptibility to hypertension. | 2014-11-13 |
20140336284 | POWDER ANTIFOAMING AGENT AND METHOD FOR PRODUCING SAME - Disclosed is a powder antifoaming agent containing: (A) a hydrophobic organopolysiloxane that has a viscosity at 25° C. of 10-100,000 mm2/s; (B) a fine silica powder; (C) a surfactant; and (D) a water-soluble encapsulating agent that is in a solid state at 25° C. This powder antifoaming agent is characterized by being obtained by spray drying a dispersion liquid that is obtained by dispersing a silicone oil compound, which is obtained by mixing the component (A) and the component (B), and the component (D) in water in the presence of the component (C), and is also characterized in that the silicone oil compound is encapsulated by the component (D) that serves as an outer shell. Since the present powder antifoaming agent does not contain water by being produced by a spray drying method, the powder antifoaming agent is free from problems of emulsion antifoaming agents such as separation and putrefaction. | 2014-11-13 |